PHOENIX, April 25, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “Company”) today announced that the Company will release its first quarter 2017 financial results on Tuesday, May 9, 2017, before the U.S. financial markets open.
Following the release of the financial results, Saeed Motahari, President and Chief Executive Officer, and Darryl S. Baker, Chief Financial Officer, will host a conference call at 10:00 a.m. Eastern Daylight Time.
Interested parties may participate in the conference call by dialing (844) 263-8304 (U.S.) or (213) 358-0958 (International), 5-10 minutes prior to the start of the call. A replay will be available shortly after the completion of the call for one week by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (International) and entering conference call ID number 14339975.
A live audio webcast and archive of the call will also be available at www.insysrx.com.
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys is developing a pipeline of products intending to address unmet medical needs and the clinical shortcomings of existing commercial products. Insys currently markets one product, SUBSYS® (fentanyl sublingual spray) but has received approval for the marketing of SYNDROS™ (dronabinol oral solution), a proprietary, orally administered liquid formulation of dronabinol that Insys believes has distinct advantages over the current formulation of dronabinol in soft gel capsule. Insys is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with high unmet need.
SUBSYS® and SYNDROS™ are trademarks of Insys Development Company, Inc., a subsidiary of Insys Therapeutics, Inc.
Contact: Lisa M. Wilson T: 212-452-2793 E: INSYS@insysrx.com
Source:Insys Therapeutics, Inc.